Related Experiment Video
Updated: Jun 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma
Kuan-Ting Kuo1, Tsui-Lien Mao, Xu Chen
1Division of Gynecological Pathology, Departments of Pathology, Gynecology/Obstetrics, and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Purpose:
Advanced ovarian clear cell carcinoma (CCC) is one of the most aggressive ovarian malignancies, in part because it tends to be resistant to platinum-based chemotherapy. At present, little is known about the molecular genetic alterations in CCCs except that there are frequent activating mutations in PIK3CA. The purpose of this study is to comprehensively define the genomic changes in CCC based on DNA copy number alterations.
Experimental Design:
We performed 250K high-density single nucleotide polymorphism array analysis in 12 affinity-purified CCCs and 10 CCC cell lines. Discrete regions of amplification and deletion were also analyzed in additional 21 affinity-purified CCCs using quantitative real-time PCR.
Results:
The level of chromosomal instability in CCC as defined by the extent of DNA copy number changes is similar to those previously reported in low-grade ovarian serous carcinoma but much less than those in high-grade serous carcinoma. The most remarkable region with DNA copy number gain is at chr20, which harbors a potential oncogene, ZNF217. This discrete amplicon is observed in 36% of CCCs but rarely detected in serous carcinomas regardless of grade. In addition, homozygous deletions are detected at the CDKN2A/2B and LZTS1 loci. Interestingly, the DNA copy number changes observed in fresh CCC tissues are rarely detected in the established CCC cell lines.
Conclusions:
This study provides the first high resolution, genome-wide view of DNA copy number alterations in ovarian CCC. The findings provide a genomic landscape for future studies aimed at elucidating the pathogenesis and developing new target-based therapies for CCCs.
Insights
This study reveals key DNA copy number alterations in ovarian clear cell carcinoma (CCC), identifying ZNF217 amplification on chromosome 20 as a significant finding. These genomic insights are crucial for understanding CCC development and therapy.
Area of Science:
- Genomics
- Oncology
- Molecular Biology
Background:
- Advanced ovarian clear cell carcinoma (CCC) is an aggressive malignancy.
- CCC often exhibits resistance to platinum-based chemotherapy.
- Limited knowledge exists on CCC's molecular genetic alterations beyond PIK3CA mutations.
Purpose of the Study:
- To comprehensively define genomic changes in CCC.
- To identify DNA copy number alterations in CCC.
Main Methods:
- Utilized 250K high-density single nucleotide polymorphism (SNP) array analysis.
- Analyzed 12 affinity-purified CCCs and 10 CCC cell lines.
- Validated discrete amplification and deletion regions in 21 additional CCCs using quantitative real-time PCR.
Main Results:
- CCC exhibits chromosomal instability comparable to low-grade serous carcinoma, but less than high-grade serous carcinoma.
- A significant DNA copy number gain region at chr20, harboring the potential oncogene ZNF217, was observed in 36% of CCCs.
- Homozygous deletions were identified at the CDKN2A/2B and LZTS1 loci.
- DNA copy number changes in fresh tissues were rarely mirrored in established CCC cell lines.
Conclusions:
- This study presents the first high-resolution, genome-wide view of DNA copy number alterations in ovarian CCC.
- The identified genomic landscape provides a foundation for future research into CCC pathogenesis.
- Findings pave the way for developing novel, targeted therapies for CCC.
More Related Videos
06:25Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence
Published on: February 10, 2023
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016